Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05108805 · ClinicalTrials.gov registry record · Phase 4
Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting
A Phase 4 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
NCT05108805: Completed Phase 4 study, sponsored by Vanderbilt-Ingram Cancer Center.
NCT05108805 is a Phase 4 study that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 25 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05108805, a Phase 4 study, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
Study Summary
We hope to demonstrate that YESCARTA can be safely administered in the outpatient setting if we closely monitor subjects with physical exams, wearable devices, and telemedicine visits and only admit those who meet specified criteria
Primary Outcome
The number of participants that received YESCARTA as outpatient therapy
Interventions
- BIOLOGICAL Axicabtagene Ciloleucel
- PROCEDURE Telemedicine Visit
- PROCEDURE Vital sign measurements
- PROCEDURE Out-Patient Clinic Visit
- PROCEDURE Blood pressure and pulse oximeter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-12-02 |
| Est. Completion | 2023-12-08 |
| Phase | Phase 4 |
What the finished NCT05108805 record still lists
NCT05108805 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 5 interventions - of which Axicabtagene Ciloleucel is the first listed.
NCT05108805 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05108805 about?
NCT05108805 is a clinical study titled "Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting". We hope to demonstrate that YESCARTA can be safely administered in the outpatient setting if we closely monitor subjects with physical exams, wearable devices, and telemedicine visits and only admit those who meet specified criteria
What is the current status of trial NCT05108805?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2021-12-02. Estimated completion is 2023-12-08.
What interventions are being tested in trial NCT05108805?
The interventions under investigation include: Axicabtagene Ciloleucel (BIOLOGICAL), Telemedicine Visit (PROCEDURE), Vital sign measurements (PROCEDURE), Out-Patient Clinic Visit (PROCEDURE), Blood pressure and pulse oximeter (PROCEDURE).
Who is sponsoring clinical trial NCT05108805?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05108805's enrollment target sits among peer trials
25 1669th of 2000 higher than 302 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI